From

Institution

Field

Type

Journal / venue: Annals of Oncology ×

Open access only Cited by patents (Lens) Include non-Aachen papers (citing/cited)

Reset

Papers 297

Sort: Cited Newest Oldest Fwci Patents ⇩ CSV

1156P Transcriptomic analysis in p53-abnormal endometrial cancer and final overall survival analyses from the DOMEC phase II trial
2025 Annals of Oncology article Medicine Endometrial and Cervical Cancer Treatments Open access

Merve Kaya, Cathalijne Post, Nadia de Gruil, Siddh van Oost, Jacqueline Maria Tromp, IA Boere, +11 more

0

citations
2745eP Isocitrate dehydrogenase 1 (IDH1) mutation testing in the phase III study of ivosidenib vs placebo in IDH1-mutant conventional chondrosarcoma (CHONQUER)
2025 Annals of Oncology article Medicine Bone Tumor Diagnosis and Treatments Open access

Silvia Stacchiotti, K. Yonemori, C. Beato, Fernando Augusto Batista Campos, A.P. Conley, C. Debruyne, +10 more

0

citations
1996P Long-term outcomes with tepotinib for clinically relevant subgroups of patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

Frank Griesinger, Roberto Ferrara, Enriqueta Felip, Egbert Frederik Smit, Rémi Veillon, Xiuning Le, +14 more

0

citations
165P Diversity in treatment benefit between adolescents and young adults (AYAs) and older adults (OA) treated in the Drug Rediscovery Protocol (DRUP)
2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access

Soemeya F. Haj Mohammad, Laurien Joanna Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Hans J.L. Timmer, Maud A. van Maren, +6 more

0

citations
805P Toxicity outcomes of patients who received UGT1A1 genotype-guided irinotecan dosing: A multicentre real-world study
2025 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access

Sofía L. J. Peeters, Niels Heersche, Doortje T.M.M. Böhm, Roselien Guiljam, Gysella Oomens, Qiong Wu, +13 more

0

citations
2749eP Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular pre-screening for IDH1 mutation in chondrosarcoma
2025 Annals of Oncology article Medicine Healthcare Regulation Open access

Jean‐Yves Blay, R. Teres Lleida, Javier Martín‐Broto, Jacco Juri de Haan, C. Debruyne, Ingrid M.E. Desar, +11 more

0

citations
1874P Long-term real-world insights on immunotherapy in non-small cell lung cancer and melanoma: Data from multiple Dutch registries
2025 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

Femke J. C. Jacobs, Lieke M. van van Disseldorp, Manon C. Wilpshaar, Eline G.M. Steenhuis, N.V. Schayk, Eline Heidenrijk, +4 more

0

citations
2320P Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study
2025 Annals of Oncology article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access

Michiel Zietse, Esther R van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Ron H.J. Mathijssen, Roelof W. F. van Leeuwen, +1 more

0

citations
285eP Treating BRAF non-V600 alterations (nonV600s) with MEK inhibitors and/or BRAF inhibitors (BRAF/MEKi): Pooled results from DRUP-like clinical trials across Europe
2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access

Katarina Puco, Laurien Joanna Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Soemeya F. Haj Mohammad, Vincent van der Noort, +10 more

0

citations
2173P Timing of first-line palliative systemic therapy in metastatic esophagogastric cancer: A nationwide analysis
2025 Annals of Oncology article Medicine Gastric Cancer Management and Outcomes Open access

Denice Kamp, Anne Maria May, Marije Slingerland, Rob H.A. Verhoeven, Hanneke W.M. van Laarhoven, Nadia Haj Mohammad

0

citations
1144P Chemo sensitivity score using an ex vivo 3D micro-tumor testing platform to predict clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer
2025 Annals of Oncology article Medicine Ovarian cancer diagnosis and treatment Open access

Judith R. Kroep, Cor Doede de Kroon, P.B. Ottevanger, Anne M. van Altena, Timothy J. P. Sijsenaar, Felix M. Behr, +5 more

0

citations
1622P Response and survival in in-transit metastatic unresectable melanoma according to treatment strategy
2025 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access

C D M Boreel, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, C.U. Blank, M. J. Boers‐Sonderen, Han J. Bonenkamp, +12 more

0

citations
818P Pharmacokinetics of 5-fluorouracil in patients treated with capecitabine carrying the c.1236G>A DPYD variant allele
2025 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access

Niels Heersche, Jonathan Emanuel Knikman, Maarten J. Deenen, Hilde Rosing, Ron H. N. van Schaik, Jos H. Beijnen, +7 more

0

citations
2238P Survival outcomes after UGT1A1 genotype-guided dosing of irinotecan: Results of a multicentre survival analysis
2025 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access

Niels Heersche, Sofía L. J. Peeters, D. Böhm, Stefan Böhringer, Roselien Guiljam, Maria E. Joosse, +13 more

0

citations
2718P Characterising treatment and overall survival of chondrosarcoma patients across Europe using real-world data (RWD): Data analysis and real-world interrogation network (DARWIN EU) cohort study
2025 Annals of Oncology article Medicine Bone Tumor Diagnosis and Treatments Open access

Peter Prinsen, Jelle Evers, Vincent K.Y. Ho, Meike van de Sande, Kimmo Porkka, Anna Hammais, +9 more

0

citations
2107P Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial)
2025 Annals of Oncology article Medicine Esophageal Cancer Research and Treatment Open access

Sanjiv S. G. Gangaram Panday, Berend J. van der Wilk, Sjoerd M. Lagarde, Camiel Rosman, Bo Jan Noordman, Maria Joanna Valkema, +14 more

0

citations
1617P Leucine-rich 2 glycoprotein 1 (LRG1) as potential systemic biomarker for response to neoadjuvant immune checkpoint blockade in stage III melanoma
2025 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

Shizhen Chen, C.C.E. De Schrijver, Huub H. van Rossum, Theodora C. Linders, M.W. Lucas, Esmée P. Hoefsmit, +12 more

0

citations
2405P PSMA PET/CT-based risk stratification in synchronous metastatic hormone-sensitive prostate cancer
2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Prostate Cancer Treatment and Research Open access

Fleur Kleiburg, Linda Heijmen, Annemieke Witteveen, Kiki van Duuren, P. Zuidgeest, Frits Smit, +2 more

0

citations
2417P De-escalation of therapy with androgen receptor pathway inhibitors or docetaxel by using PSMA PET/CT in metastatic castration-resistant prostate cancer patients: study results from a Dutch cohort
2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Prostate Cancer Treatment and Research Open access

Kim J. M. van der Velden, Sietse van Mossel, Fleur Kleiburg, Lioe‐Fee de Geus‐Oei, Tom van der Hulle, Malou C. P. Kuppen, +3 more

0

citations
1616P Neoadjuvant pembrolizumab in resectable stage III melanoma: Real-world data from the nationwide Dutch Melanoma Treatment Registry
2025 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access

C D M Boreel, Alfons J.M. van den Eertwegh, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, C.U. Blank, Willeke A.M. Blokx, +13 more

0

citations
2646P The pharmacologic effects of using cabozantinib with a light breakfast: The SKIPPY1 study
2025 Annals of Oncology article Medicine Renal cell carcinoma treatment Open access

Amy Rieborn, Niels A.D. Guchelaar, Teun van Gelder, Hans A. J. Gelderblom, Saskia A. C. Luelmo, Paul Hamberg, +4 more

0

citations
2273O Routes for access to off-label treatments: A comparative analysis of 19 European countries
2025 Annals of Oncology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access

A. Huisman, Hans J.L. Timmer, Lonneke Timmers, Hans A. J. Gelderblom, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

0

citations
2218P REACtiVe-2: Phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer
2025 Annals of Oncology article Medicine Pancreatic and Hepatic Oncology Research Open access

Songul Kucukcelebi, Freek R. van ‘t Land, Marta Homs, Marcella Willemsen, A. Onrust-van Schoonhoven, Nina E. M. Rozendaal, +12 more

0

citations
1615P Health-related quality of life in the phase III NADINA trial: Neoadjuvant vs adjuvant checkpoint blockade in stage III melanoma
2025 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

Maarten Egeler, J. Lijnsvelt, M.W. Lucas, Victoria G. Atkinson, Muhammad Adnan Khattak, Miles Cameron Andrews, +14 more

0

citations
2293P High off-label use in paediatric oncology: A need for policy reform
2025 Annals of Oncology article Medicine Pharmaceutical studies and practices Open access

Hans J.L. Timmer, A. Huisman, Hans A. J. Gelderblom, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

0

citations